Myriad Genetics Shares Fall ~1% Over Last Min.; Traders Attributing To Comments From The Capitolist SeekingAlpha Contributor 'Myriad: FOIAs Reveal 50% Downside As Majority Of EBITDA Potentially At Risk From Reduced Reimbursement Rates'